Holen Sie sich die Stockscreener-App
0.9867
0.85%
-0.0118
Schlusskurs vom Vortag:
$0.9985
Offen:
$0.9985
24-Stunden-Volumen:
214.14K
Relative Volume:
0.49
Marktkapitalisierung:
$76.53M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-20.59M
KGV:
-2.9471
EPS:
-0.3348
Netto-Cashflow:
$-17.99M
1W Leistung:
-1.98%
1M Leistung:
-21.43%
6M Leistung:
-10.81%
1J Leistung:
-36.13%
1-Tages-Spanne:
$0.98
$0.9985
1-Wochen-Bereich:
$0.9701
$1.09
52-Wochen-Spanne:
$0.8401
$1.75
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Firmenname
Oncolytics Biotech Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie ONCY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ONCY | 0.9867 | 76.53M | 0 | -20.59M | -17.99M | -0.3348 |
| VRTX | 449.95 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.89 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.92 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.88 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.22 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-10-06 | Eingeleitet | Maxim Group | Buy |
| 2021-02-17 | Eingeleitet | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Aktie (ONCY) Neueste Nachrichten
HC Wainwright Has Negative Estimate for ONCY FY2024 Earnings - MarketBeat
HC Wainwright Issues Negative Forecast for TSE:ONC Earnings - MarketBeat
Leede Financial Weighs in on TSE:ONC FY2024 Earnings - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Downgraded to Moderate Buy Rating by Leede Financial - Defense World
Oncolytics Biotech (TSE:ONC) Upgraded at Raymond James - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Upgraded at Raymond James - Defense World
Oncolytics Biotech (TSE:ONC) Upgraded by Raymond James to Moderate Buy Rating - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Downgraded to "Moderate Buy" Rating by Leede Financial - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Stock Rating Upgraded by Raymond James - MarketBeat
Research Analysts Issue Forecasts for ONCY FY2024 Earnings - Defense World
FY2028 EPS Estimates for TSE:ONC Boosted by HC Wainwright - MarketBeat
Raymond James Has Bearish Forecast for ONCY FY2024 Earnings - MarketBeat
Biotech Companies’ Q3 Updates: Promising Cancer Treatments on the Horizon - Baystreet.ca
Oncolytics Biotech (NASDAQ:ONCY) Given "Buy" Rating at HC Wainwright - MarketBeat
Biotech Companies' Q3 Updates: Promising Cancer Treatments On The Horizon - Barchart
Oncolytics Biotech Inc (ONCY) Q3 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Palantir Technologies Inc Cl A (PLTR-N) QuotePress Release - The Globe and Mail
Oncolytics Biotech Inc (ONCY) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Management - GuruFocus.com
Oncolytics Biotech Inc (ONCY) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech® Inc. - Baystreet.ca
Oncolytics Biotech Inc reports results for the quarter ended September 30Earnings Summary - XM
Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights - PR Newswire
Oncolytics Bio (ONC-T) QuotePress Release - The Globe and Mail
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights - Marketscreener.com
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights – Company AnnouncementFT.com - Financial Times
Oncolytics Biotech (TSE:ONC) Shares Cross Above 200-Day Moving AverageHere's Why - MarketBeat
International Assets Investment Management LLC Sells 24,069 Shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) - Defense World
Oncolytics Biotech (TSE:ONC) Stock Passes Above 200-Day Moving AverageShould You Sell? - MarketBeat
Oncolytics Biotech® Announces Fireside Chat at the Cantor Global Healthcare Conference - GuruFocus.com
Oncolytics Biotech Inc. (NASDAQ:ONCY) Sees Significant Increase in Short Interest - MarketBeat
What is Oncolytics Biotech, Inc. (ONCY) Stock Return on Shareholders’ Capital? - SETE News
Oncolytics Biotech (TSE:ONC) Stock Price Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
Biotech Advances Gain Momentum Amid October’s Rising Breast Cancer Rates and Awareness Efforts - Baystreet.ca
Ratio Analysis: Unpacking Oncolytics Biotech, Inc. (ONCY)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
What was Oncolytics Biotech, Inc. (ONCY)’s performance in the last session? - US Post News
Oncolytic Virus Therapy Market Set to Witness Significant Growth by 2024-2031:Oncolytics Biotech Inc, Circio - EIN News
Stocks In Play: Oncolytics Biotech® Inc. - Barchart
Oncolytics Biotech (NASDAQ:ONCY) Stock Price Down 5.3%Here's Why - MarketBeat
ONCY Stock Up on Regulatory Update From Breast Cancer Program - MSN
A new trading data show Oncolytics Biotech, Inc. (ONCY) is showing positive returns. - SETE News
Quarterly Snapshot: Quick and Current Ratios for Oncolytics Biotech, Inc. (ONCY) - The Dwinnex
Oncolytics Biotech (TSE:ONC) Shares Down 7.9%Here's Why - MarketBeat
Examining Oncolytics Biotech, Inc. (ONCY) more closely is necessary - US Post News
Oncolytics seeking FDA meeting to discuss registration-enabling study - MSN
ONCY’s 52-Week Rollercoaster: From $0.84 to $2.10 – What’s Next for Investors? - The InvestChronicle
Global cancer cases surge while biotech firms accelerate treatment innovations - Benefits and Pensions Monitor
Oncolytics targets accelerated approval for oncolytic virus therapy - Yahoo Finance
Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path - The Malaysian Reserve
Oncolytics Biotech (TSE:ONC) Stock Price Up 11.8%Should You Buy? - MarketBeat
Stocks In Play: Oncolytics Biotech® Inc. By Baystreet.ca - Investing.com Canada
Finanzdaten der Oncolytics Biotech Inc-Aktie (ONCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):